Cytoreductive nephrectomy in the current treatment algorithm-Reference-Cited by-同舟云学术

Cytoreductive nephrectomy in the current treatment algorithm

Published:2019-01 Issue: Volume:11 Page:175883591987902
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Kuusk Teele¹,Szabados Bernadett²,Liu Wing Kin³,Powles Thomas²,Bex Axel⁴⁵

Affiliation:

1. Royal Free Hospital, Department of Urology, Renal Cancer Unit, London, UK

2. Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK

3. Royal Free Hospital, Department of Medical Oncology, London, UK

4. Royal Free Hospital, Department of Urology, Renal Cancer Unit, University College London, Division of Surgical and Interventional Sciences, London, UK

5. The Netherlands Cancer Institute Division of Surgical Oncology, Department of Urology, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands

Abstract

The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether deferred CN in combination with sunitinib can be used to identify patients with inherent targeted therapy resistance. In the current review, we provide a comprehensive discussion of two randomized studies and the current evidence with up-do-date algorithms for treating primary metastatic clear-cell renal cell carcinoma in the era of targeted therapy and immune-checkpoint inhibition.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758835919879026

Reference27 articles.

1. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

2. Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma

3. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

4. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

5. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytoreductive Nephrectomy in Select Primary Metastatic Renal Cell Carcinoma Patients: A Comprehensive Nationwide Outcome Analysis;Cancers;2024-03-12

2. A Case of Metastatic Renal Cell Carcinoma to the Maxillary Sinus Initially Presenting as Recurrent Epistaxis;JU Open Plus;2023-12

3. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy;The Oncologist;2023-06-27

4. Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives;Medicina;2023-04-15

5. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis;International Immunopharmacology;2022-07